Нейрофармакологическое изучение механизмов взаимодействия типичных и атипичных нейролептиков с ингибиторами каналов кальция: Роль дофаминергических систем мозга
![Диссертация: Нейрофармакологическое изучение механизмов взаимодействия типичных и атипичных нейролептиков с ингибиторами каналов кальция: Роль дофаминергических систем мозга](https://westud.ru/work/4884273/cover.png)
Диссертация
Как было показано в ходе наших экспериментов, циннаризин, относящийся к группе производных пиперазина (IV группа ИКК), в различных дозах проявлял противоположные по знаку свойства. Так, при введении данного соединения в дозе 25 мг/кг, наблюдалась активация всех форм поведения животного, тогда как в дозе 50 мг/кг циннаризин проявлял отчетливое угнетающее действие, снижая значения всех… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
- ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Дофаминергические системы мозга
- 1. 2. Современные представления о структуре и функциональ ной роли дофаминовых рецепторов
- Нейрофармакологическая и нейрохимическая характеристика атипичных нейролептиков. Роль дофаминовых рецепторов в механизме действия атипичных нейролептиков
- 1. 4. Психофармакологические свойства ингибиторов каналов кальция
- 1. 4. 1. Антидепрессантные свойства ИКК
- 1. 4. 2. Противосудорожные свойства ИКК
- 1. 4. 3. Анксиолитические свойства ИКК
- 1. 4. 4. Взаимодействие ИКК с дофаминергической системой
- 1. 4. Психофармакологические свойства ингибиторов каналов кальция
- 2. 1. Методика оценки локомоторной активности животных в «открытом поле» (Open- field test)
- 2. 2. Определение содержания моноаминов и их метаболитов в структурах мозга крыс
- 2. 3. Статистическая обработка полученных результатов
- 3. 1. Изучение эффектов нейролептиков различных групп и ингибиторов каналов кальция на поведенческие показатели крыс в тесте «открытое поле»
- 3. 1. 1. Исследование эффектов галоперидола, сульпирида, клозапина и оланзапина на поведение животных в тесте «открытое поле»
- 3. 1. 2. Изучение влияния верапамила на параметры двигательной активности крыс в «открытом поле»
- 3. 1. 3. Изучение влияния дилтиазема на поведенческие характеристики крыс в тесте «открытое поле»
- 3. 1. 4. Изучение влияния нифедипина на двигательную активность крыс в тесте «открытое поле»
- 3. 1. 5. Изучение влияния циннаризина на поведенческие характеристики крыс в тесте «открытое поле»
- 3. 2. Нейрохимическое изучение эффектов нейролептиков различных групп и ингибиторов каналов кальция на содержание нейротрансмиттеров в структурах мозга крыс
- 3. 2. 1. Нейрохимическое изучение эффектов галоперидола, клозапина и оланзапина на содержание моноаминов и их метаболитов в структурах мозга крыс
- 3. 2. 2. Нейрохимическое изучение эффектов ингибиторов каналов кальция на содержание моноаминов и их метаболитов в структурах головного мозга крыс
- 3. 2. 3. Нейрохимическое изучение совместного введения верапамила и оланзапина на содержание нейротрансмиттеров в структурах мозга крыс
Список литературы
- Ясмятов В.Й., Баьыров Р. Б., Мирзяйев Х. М., Гянийев М. М. Калсиум канал-лар блокаторларынын узунмцддятли истифадясинин мяркязи синир систе-минин ойаныглыьа тясири // Азярбажан яжзачылыг ъурн. Бакы, 2002, № 2, с. 41−43
- Ясмятов В.Й., Мирзяйев Х. М., Йагубов К. М., Шадлински Е. А. Калсиум ка-налларынын блокаторларынын анксиотипик хцсусиййятляри // Акад. Зцлфц-гар Мяммядовун 100 иллик йубилейинин йекун елми конфрансынын тезис-ляр топлусу. Бакы, 2003. с. 186−187.
- Авруцкий Г. Я., Недува А. А. Лечение психических больных. М.: Медицина, 1988.
- Арушанян Э.Б. Мезолимбическая система мозга и ее участие в действии психотропных веществ // Фармакол. и токсикол, 1977, № 5, С.623−630.
- Арушанян Э.Б., Попов А. В., Попова А. П. Особенности минутных колебаний галоперидоловой каталепсии вклад разных отделов стриатума в их формировании у крыс // Ж. Высш. нерв, деят., 1992, Т.42, № 3, С. 573−582.
- Асметов В.Я. Влияние блокаторов кальциевых каналов на эффекты нейролептиков и финамина у крыс // Эксперим. клин, медицина, Тбилиси, 2004, № 4, с. 16−19.
- Асметов В.Я. Роль ионов кальция в организме и их антагонистов при патологии центральной нервной системы // Саьламлыг. Баку, 2004, № 8, с. 100 104.
- Барков Н.К. К вопросу о механизме действия карбидина // Фармакол. токсикол. 1973, Т.36, С.154−157.
- Ю.Бертрам Г. Катцунг Базисная и клиническая фармакология. Пер. с англ. Подред. Э. Э. Звартау. М.: БИНОМ, СПб.: Невский диалект, 2000, Т.1. с.524−536
- П.Бондаренко Н. А. Избирательное влияние нейролептиков на дофаминозави-симое нарушение поведения крыс в тесте экстраполяционного избавления // Бюлл. экспер. биол. мед. 1990, Т.110, №.11, С.506−508.
- Гайнетдинов P.P., Мирошниченко И. И., Кудрин B.C., Богданов М. Б. и др. Сравнительное изучение нейрохимических профилей стереоизомеров карбидина. // Ж. Экспер. и клин, фармакол., 1993, Т.56, №.1, С.24−27.
- Н.Ганиев М. М. Изучение дофаминергических механизмов действия атипичных нейролептиков: нейрофармакологический и нейрохимический анализ. Авто-реф.дис.докт. мед.наук. М., 1994.
- Ганиев М.М. Влияние стереоизомеров карбидина на содержание медиатор-ных аминокислот в структурах головного мозга крыс // Азмеджурнал, 1999, № 4, с. 53−55.
- Ганиев М.М. Фармакологическая коррекции нарушений памяти вызванных нейролептиками // Medical journal vita, 2000, № 3−4, p. 43−47.
- Ганиев M.M., Алиев А. Н., Ахундова С. К., Тагизаде Т. П. Эффект атипичных нейролептиков сульпирида и тиаприда при интрацеребральном введении в неостриатум / III съезд фармацевтов Азербайджана. Ноябрь, 1988, Баку, с.197−199.
- Ганиев М.М., Асметов В. Я., Гурбанов Г. Н. и др. Сравнительный эффект типичных и атипичных нейролептиков на фоне активации пресинаптических дофаминергических рецепторов / В сб. «Итоговая конференции АМУ им.
- Н.Нариманова за 1993 год». Баку, Табиб.
- Ганиев М.М., Асметов В. Я., Гулиева С. Т., Ягубов К. М. Сравнительный анализ возможного участия Дз подтипа дофаминовых рецепторов в механизме действия типичных и атипичных нейролептиков // Азмеджурнал, 2001, № 1, с. 22−25.
- Ганиев М.М., Гурбанов Г. Н., Алиев А. Н., Раевский К. С. Изучение эффектов типичных и атипичных нейролептиков на обучение и память / III Республиканская биохимическая конференция. Баку, 1997, с. 69−72.
- Ганиев М.М., Гусейнов Д. Я., Мирзоев Х. М., Таги-заде Т.П., Алиева С. А. Роль дофаминергической системы мозга в механизме действия нейролептиков // Доклады АН Азербайджанской ССР, 1988, № 8, с. 68−72.
- Калинин В.В. Влияние нейролептиков, мидантана и ДОФА на апоморфино-вую стереотипию у крыс // Фармакол. Токсикол, 1977, Т.40. №.1. с. 16−19.
- Козловская М.М., Вальдман А. В. / В кн.: Нейрофармакология процессов центрального регулирования. JL, 1969. с.126−198.
- Кудрин B.C., Хетеи Л., Моргенштерн Р., Раевский К. С., Ольснер В. Влияние атипичных нейролептиков карбидина и сульпирида на биосинтез дофамина в синаптосомах прилежащего ядра крыс // Фармакол. токсикол. 1987. № 2. С.16−19.
- Легеза В.Н., Камышина М. Ф., Жарковская И. В., Шегоян М. Г., Мартиросов К. С. Влияние диметпрамида и метаклопрамида на скорость оборота катехо-ламинов в подкорково-стволовых структурах головного мозга крыс // Фармакол. токсикол. 1986, Т.49. с.25−27.
- Маликова Л.А., Арефолов В. А. Влияние карбидина на кругооборот дофамина в полосатом теле мозга крыс // Фармакол. токсикол. 1980, Т.48, №.8, с.310−318.
- Машковский М.Д. Лекарственные средства. М.: Новая волна, 2000, 14 изд. Т.1, с.66−74
- Минеева М.Ф. Механизмы действия нейролептиков // Итоги науки и техники. ВИНИТИ. Фармакология. Химотерапевтические средства. 1987, Т. 15, с. 170−239.
- Минеева М.Ф., Сипилина Н. М., Загоревский В. А., Раевский К. С. Стереоспе-цифичность действия карбидина на активность тирозингидроксилазы мозга // Хим. фарм. журн. 1984, Т. 18, с. 1159−1168.
- Мирошниченко И.И., Кудрин B.C., Раевский К. С. Влияние карбидина, сульпирида и галоперидола на содержание моноаминов и их метаболитов в структурах головного мозга крыс // Фармакол. токсикол. 1988, Т.51, № 2, с.26−29.
- Зб.Отеллин В. А., Арушанян Э. Б. / В кн.: Стрионигральная система. М.: Медицина, 1989.
- Раевский К.С. Фармакология нейролептиков. М.: Медицина. 1976.
- Раевский К.С. Нейрохимическая стратегия и изучение механизма действия современных антипсихотических веществ // Вестн. РАМН. 1992, № 7, с. 2125.
- Раевский К.С. Дофаминовые рецепторы мозга: структура, функциональнаяроль, модуляция психотропными веществами // Вопр. мед. химии. 1997, Т.43, с.553−565.
- Раевский К.С. Функциональная роль и фармакологическая модуляция дофа-минергических систем мозга // Вестник РАМН. 1998, № 8, с. 19−24.
- Раевский К.С. Нейролептики и антидепрессанты: современное состояние проблемы // Междунар. Мед. Журн. 2002, № 1−2, с. 192−198.
- Alander Т., Anden N.E., Grabowska-Anden М. Metoclopramide and sulpiride as selective blocking agents of pre- and postsynaptic dopamine receptors // Naunyn-Schmiedeberg's Arch. Pharmacol. 1980. V.312. P. 145−150.
- A1-Tajir G., Starr M.S. Anticonvulsant action of SCH 23 390 in the striatum of the rat // Eur. J. Pharmacol. 1990. V.191. P.329−336.
- Altar C.A., Boyor W.C., Kim H.S. Discriminatory roles for Dt and D2 dopamine receptor subtypes in the in vivo control of neostriatal cyclic GMP // Eur. J. Pharmacol. 1990. V. 181. P. 17−21.
- Altar C.A., Boyar W.C., Wasley A., Gerhardt S.C., Liebman J.M. et al. Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists //Naunyn-Schmiedeberg's Arch. Pharmacol. 1988. V.338. P.162−168.
- Altar C.A., Wasley A.M., Neale R.F., Stone G.A. Typical and atypical antipsychotic occupancy of D2 and HT2 receptors: an autoradiographic analysis in rat brain//Brain Res. Bull. 1986. V.16. P.517−525.
- Amalric M., Berhow M., Polis I., Koob G.F. Functional differences between D1 and D2 dopaminergic receptors in a conditioned motor task // Psychophar-macol. 1990. V.101(Suppl.). P.3.
- Anden N.E., Dahlstrom A., Fuxe K., Larsson K. Functional role of the nigroneos-triatal dopamine neurons // Acta Pharmacol. Toxicol. (Kbh). 1966a. V.24. P.263−274.
- Anden N.E., Fuxe K., Hamberger В., Hokfelt T. A quantative study on the nigro-neostriatal dopamine neuron system in the rat //Acta Physiol. Scand., 1966b. V.67. P.306−312.
- Anden N.E., Nilsson H., Rose E., Thornstrom U. Effects of B-HT 920 and B-HT933 on dopamine and noradrenaline autoreceptors in the rat brain // Acta Pharmacol. Toxicol. 1983. V.52. P.51−56.
- Anden N.E., Stock G. Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system // J.Pharm.Pharmacol. 1973a. V.25. P.346−348.
- Anden N.E., Strombom U., Svensson Т.Н. Dopamine and noradrenaline receptor stimulation- Reversal of reserpine-induced suppression of motor activity // Psy-chopharmacol. 1973b. V.29.P.289−298.
- Andersen P.H., Braestrup C. Evidence for different states of the • dopamine Di receptor: clozapine and fluperlapine may preferentialy label an adenylate cyc-lase-coupled state of the Dx receptor//J. Neurochem. 1986. V.47. P. 1822−1831.
- Andersen P.H., Gingrich J.A., Bates M.D., et.al. Dopamine receptor subtypes: beyond the Di/D2 classification // Trends Pharmacol.Sci. 1990. V. l 1. P.231−236.
- Andersen P.H., Nielsen E.B., Gronvald F.C., Braestrup C. Some atypical neuroleptics inhibit 3H. SCH 23 390 binding in vivo // Eur. J. Pharmacol. 1986. V. l20. P.143−144.
- Andrew F., Rennic C.H. Clozapine. A Review of its pharmacological properties and therapeutic use in schizophrenia // Drugs. 1990. V.40. P.722.
- Araihe A., Ohno J., Sasa M., Taraori S. Excitatory and inhibitory effects of dopamine on neuronal activity of the caudate nucleus neurons in vivo // Brain Res. 1987. V.418. P.262−272.
- Arnt J. Hyperactivity induced by stimulation of separate dopamine D-l and D-2 receptors in rats with bilateral 6-OHDA lesions // Life Sci. 1985. V.37. P.717−723.
- Arnt J., Hyttel J. Dopamine D2 agonists with high and low efficacies: differentiation by behavioural techniques // J. Neural Transm. 1990b. V.80. P.33−50.
- Asghari V., Schoots О., Van Kats S., Ohara K. et al. // Mol. Pharmacol. 1994. V.10. P.364−373.
- Baik J.H., Picetti R., Saiardi A., Thiriet G. et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors // Nature. 1995. V.377. P.424−428.
- Baldessarini G., Frankenburg F. Clozapine: a novel antipsychotic agent // N. Engl. J. Med. 1991. V.324. P.746−754.
- Bartholini G., Haefely W., Jalfre M., Keller H.H., Pletscher A. Effects of clozapine on cerebral catecholaminergic neurone systems // Br. J. Pharmacol. 1972.V.46. P.736−740.
- Beasley C.M., Tolllefson G., tran P. et al. Olanzapine versus placebo: results of a international double-blind olanzapine test // Psychopharmacol. 1996. V.124. P.159−167.
- Bergstrom D.A., Kreiss D.S., Gonzales A.M., Huang K.-X. et al. // Neuropsycho-pharmacol. 1994. V.10. P.237S.
- Berry S.A., Gudelsky G.A. Di receptor function to inhibit the activation of tu-beroinflundibular dopamine neurons //J. Pharmacol. & Exp. Ther. 1991a. V.254. P.677−682.
- Berry S.A., Gudelsky G.A. Effects of D2 dopamine agonists on tuberoinfundibular dopamine neurons//Neuropharmacol. 1991b. V.30. P.961−965.
- Beuzen J.-N., Taylor N., Wesnes K., Wood A. The effects of olanzapine on cognition and psychomotor function in healthy elderly volunteers // J. Psychopharmacol. 1999. V.13. P.152−158.
- Blaha C.D., Lane R.F. Chronic treatment with classical and atypical antipsychotic drugs differentially decreases dopamine release in striatum and nucleus accum-bens in vivo // Neurosci. Lett. 1987. V.78. P. 199−204.
- Blin O. A comparative review of new antipsychotics // Can.J.Psychiatry. 1999. V.44. P.235−244.
- Bolden C., Cusack В., Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells // J. Pharm. Exp. Ther. 1992. V.260. P.576−580.
- Borison R.L., Diamond B.L. Regional selectivity of neuroleptic drugs: an argument for site specificity // Brain Res.Bul. 1983. V. l l.P.215−218.
- Bortel-Badura M., Pudeeko A., Trzeciak H.I. The behavior of rats after long-term treatment with atypical neuroleptics // Pol. J. Pharmacol. Pharm. 1992. V.44. (Suppl.) P.101−102.
- Braun A.R., Chase T.N. Behavioral effects of chronic exposure to selective D-l and D-2 dopamine receptor agonists // Eur. J. Pharmacol. 1988. V. l47. P.441−451.
- Breier A. Clozapine and noradrenergic function, support for a novel hypothesis for superior efficacy // J. Clin. Psychiatr. 1994. V.55. P. 122−125.
- Brooderson R.J., White F.J., Galloway M.P. Inhibition of dopamine synthesis in striatal slices by the D1 agonist SKF 38 393 in not mediated by D1 dopamine receptors // Synapse. 1990. V.6. P.395−397.
- Brown E.M., Attie M.F., Reen S., Gardner D.G., Kebabian J.W., AurbachG.D. Characterization of dopaminergic receptors in dispersed bovine parathyroid cells // Mol. Pharmacol. 1980. V. l8. P.335−340.
- Brown J.H., Makman M. Stimulation by dopamine of adenylate cyclase in retinal homogenates and of adenosine -3,5- cyclic monophosphate formation in intact retinal // Proc. Natl. Acad. Sci .USA. 1972. V.69. P.539−543.
- Bymaster F.P., Hemrick-Luecke S.K., Perry K.W. et al. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonine, alpha-adrenergic andmuscarinic receptors in vivo in rats 11 Psychopharmacol. 1996. V.124. P.87−94.
- Caine S.B., Koob G.F. Modulation of cocain self-administration in the rat through D-3 dopamine receptors // Sci. 1993. V.260. P. 1814−1816.
- Carlsson A. Receptor-mediated control of dopamine metabolism // In. Usdin E., Bunney W.E. (eds). Pre- and postsynaptic receptors. N.Y. 1975. P.49−63.
- Casey D.E. Neuroleptic-induced acute extrapyramidal syndromes ans tardive dyskinesia // In.: Hirsch S.R., Weinberger D.R. (Eds.). Schizophrenia UK. 1995. London, Blackwell Sci. P.546−565.
- Chang W.H., Chen T.Y., Yeh B.K. Time-response curves of homovanilic acid in caudate and pre- frontal cortex following acute neuroleptic administration // Psychopharmacol. 1987. V.93. P.403−404.
- Chauchard M.H. Psychopharmacologie du dogmatil // Sem. Hosp. Paris. 1985. V.61.P.2186−2190.
- Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and AlO midbrain dopaminergic neurons // J. Neurosci. 1983. V.3. P. 1607−1619.
- Civelli O., Bunzow J.R., Grandy D.K. Molecular diversity of the dopamine receptors // Ann. Rev. Pharmacol. Toxicol. 1993. V.33. P.281.
- Clark D., White F.J. Di dopamine receptor: the search for a function- a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications // Synapse. 1987. V.l. P.347−388.
- Code R.A., TangA.H. Yawning produced by dopamine agonists in rhesus monkeys // Eur. J. Pharmacol. 1991. V.201. P.235−238.
- Cordiner Т.Н., Lewis J.M., Shore P.A., Distribution of clozapine in the rat: localization in lung//J. Phamacol. & Exp.Ther. 1978. V.206. P.151−157.
- Costall В., Naylor R.J. Behavioural aspects of dopamine agonists and antagonists, In: The neurobiology of dopamine (Eds.: Horn A.S., Korf J., and Weste-rink B.H.C.) // Academic Press, London, 1979. P.555−576.
- Coward D.M., Imperato A., Urweler S., White T.G. Biochemical and behavioral properties of clozapine // Psychopharmacol. 1989. V.99. P. S6-S12.
- Coyle J.T., Enna S. J 11 Neuroleptics: neurochemical, behavioural and clinical perspectives. Raven Press, N.Y. 1983.
- Crow T.J., Deakin J.F.W., Longden A. The nucleus accumbens: A possible site of antipsychotic action of neuroleptic drugs // Psychol. .Med. 1977. V.7. P.213−221.
- Crow T.J., Johnstone E.C., Longden A., Owen F. Dopamine and Schizophrenia // Advances in biochemical psychopharmacology. Raven Press, N.Y. 1978. V.19. P.301−310.
- Daly S.A., Waddington J.L. Behavioral effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other «D-2-like» agonists // Neuro-pharmacol. 1993. V.32. P.509−510.
- Davis A.S., Jenner P., Marsden C.D. Apomorphine induces grooming behaviour in rats pretreated with sulpride // Br. J. Pharmacol. 1985. V.86 (Suppl.). P.434.
- DearryA., Gingrich J.A., Falardeau P., Fremeau R.T.Jr. etal. Molecular cloning and expression of the gene for a human D1 dopamine receptor // Nature (London). 1991. V.347. P.72−76.
- Deutcsh A., Moghaddam В., Innis R., Crystal J. et al. Mechanisms of action of atypical antipsychotic drugs. Implication for novel therapeutic strategies for schizophrenia. Schizophr. Res. 1991. V.4. P. 121−156.
- Di Chiara G., Morelli M., Acguas E., Carboni E. Functions of dopamine in the extrapyramidal and limbic systems: clues for the mechanism of drug actions // Ar-zneimit. Forsch. 1992. V.42. P.231−237.
- DourishC.T., Herbert E.N., Iverssen S.D. Blockade of apomorphine-induced yawning in rat by the dopamine autoreceptor antagonist (+) Aj-76 // Neurophar-macol. 1989. V.28. P.1423−1425.
- Edwards E., Ashby Ch.R., Wang R.Y. The effect of typical and atypical antipsychotic drugs on the stimulation of phosphoinositide hydrolysis produced by the 5-HT3 receptor agonist 2-methyl-serotonin // Brain Res. 1991. V.545. P.276−278.
- Eichenberger E. Pharmacology of fluperlapine compared with clozapine // Arz-neimit. Forschung. 1984. V.34. P. 110−113.
- Ellenbroeck B.A. Treatment of schizophrenia: a clinical and preclinicalevaluation of neuroleptic drugs // Pharmacol. Ther. 1993. V.57. P. l-78.
- Elliot P.N.S., Jenner P., Huising G., Marsden C.D., Millor R. Substitued benza-mides as cerebral dopamine antagonists in rodents // Neuropharmacol. 1977. V.16. P.333−342.
- EngelG., Richardson B.R., DonatschP., StadlerP. A new class of drugs: 5-HT3 receptor antagonists // Triangle. 1986. V.25. P. 123−130.
- Ernest A.M. Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS // Psychopharmacol. 1965. V.7. P.391−399.
- Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs // Arch. Gen. Psychiat 1988. V.45.P.71.
- Farde L., Wiesel F.A., Nordstrom A.L., Sedvall G. Di and D2 dopamine receptor occupancy during treatment with conventional and atypical neuroleptics // Psychopharmacol. 1989. V.99. P. S28-S31.
- Feenstra M.G.P., Sumners C., Goedemoed J.H., de Vries J.B. et al. A comparison of the potencies of various dopamine receptor agonists in models for pre-and postsynaptic receptor activity // Naunyn-Schmiedeberg's Arch.Pharmacol. 1983. V.324. P.108−115.
- FittonA., HeelR.C. Clozapine: A review of its pharmacologycal properties and therapeutic use in schizophrenia // Drug. 1990. V.40. P.722−747.
- Freedman S.B., Peat J.A., Woodruff G.N. 3H-Sulpiride, a ligand for neuroleptic receptors//Neuropharmacol. 1981. V.20. P.1323−1326.
- Fuller R.W., Snoddy H.D. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine, an antipsychotic drug candidate // Res. Commun. Chem. Pathol. Pharmacol. 1992. V.77. P.87−93.
- Gao X.-M., Sakai K., Tamminga C.A. Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared with halo-peridol // Neuropsychopharmacol. 1998. V. 19. P.428−433. c
- GauchR., Michaelis W. The metabolism of 8-chloro-ll-(4-methyl 4-pipera-zinyl)-5H-dibenzo b, c. [1,4] diazepine (clozapine) in mice, dogs and human subjects//Farmacol. 1971. V.26. P.667−681.
- Geffen L.B., Jessell T.M., Cuello A.C., Iversen L.L. Release of dopamine from dendrites in rat substantia nigra // Nature. 1976. V.260. P.258−260.
- Gerlach J., Peacock L. New antipsychotics- the present status // Int. Clin. Psy-chopharmacol. 1995. V.10. P.39−48.
- Gingrich J.A., Caron M. Recent advances in the molecular biology of dopamine receptors //Ann. Rev. Neurosci. 1993. V.16. P.299−321.
- Giros В., Martres M.P., Sokoloff P., Schwartz J.C. Clonage du gene du recep-teur dopaminergique D3 human et identification de son chromosome // C. R Acad. Sci. Paris. 1990. V.311. P.501−508.
- Goldberg L.I. Cardiovascular and renal actions of dopamine: Potential clinical applications // Pharmacol. Rev. 1972. V.24. P. 1−29.
- Goldberg L.I., Kohli J.D. Peripheral pre- and postsynaptic dopamine receptors: Are they different from dopamine receptors in the central nervous system // Commun. Psychopharmacol. 1979. V.3. P.447−456.
- Goldstein J. Pre-clinical pharmacology of new atypical antipsychotics in late stage development // Expert Opin. on Invest. Drugs, 1995, V.4, P.291−298.
- Goldstein J. Preclinical tests that further distinguish the pharmacological prp-perties of a clozapine-like atypical antipsychotic // In: Benninger R.J., Paloma T. (Eds.) Dopamine Disesase States? 1996. Madrid, P.299- 306.
- Goldstein J. The new generation of antipsychotic drugs: how atypical are they?
- Int. J.Neuropsychopharmacol. 2000. V.3. P. 339−349.
- Gainetdinov R.R., Bogdanov M.B., Pogorelov V.M., KudrinV.S., Rayev-sky K.S. Stereoisomers of the atypical neuroleptic carbidine modulate striatal dopamine release in awake rats // Neuropharmacol. 1991.V.30. P.1251−1254.
- Gurevich E., Kung M.-P., Bordelon Y., Joyce J.N. // Neuropsychopharmacol. 1994. V.10. P.236S.
- Gyertyan I., Randy A. Comparison of effects of neuroleptic compaunds on spontaneous and conditioned behavior // Eur. J. Pharmacol. 1990. V.183. P.1893−1894.
- Haggstrom J.E., GunneL.M., Carlsson A., WikstromH. Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in cebus monkeys with persistent neuroleptic-induced dyskinesias // J. Neur. Transmiss. 1983. V. 58. P.135−142.
- Hall H., Sallemark M., Jerning E. Effects of remoxipride and some related new substituted salicylamides on rat brain receptors //Acta pharmacol. toxicol. 1986. V.58. P.61−70.
- Hand Т.Н., HuX.T., WangR.Y. Differential effects of acute clozapine and haloperidol on the activity of ventral tedmental (AlO) and nigrostriatal (A9) dopamine neurons // Brain Res. 1987. V.415. P.257−269.
- Hjorth S., Carlsson A., Wikstrom H., Lindberg P. et al. 3-PPP, a new centrally acting DA receptor agonist with selectivity for autoreceptors // Life Sci. 1981. V.28. P.1225.
- Hjorth S., Clark D., Carlsson A. Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation // Eur. J. Pharmacol. 1988. V.152. P.207−215.
- Hokfelt Т., Ljungdahl A., Fuxe K., Johansson O. Dopamine nerve terminals in the rat limbic cortex: Aspects of the dopamine hypothesis of schizophrenia // Sci. 1974, V.184. P.177−179.
- Honma Т., Fukushima H. Effects of bilateral lesions in the striatum or nucleus accumbens on the cataleptogenic activity of neuroleptics in rats // Jap. J. Pharmacol. 1978. V.28.P.231−238.
- HornA.S., Feenstra M.G.P., GrolC.J., RollemaH. et al. Multiple dopamine receptors: fact, fiction or confusion? // Pharm. Weekblad Sci. Ed. 1981. V.3. P.145−165.
- Ichikawa J., Kuroki Т., Dai J., Meltzer H.Y. Effects of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accum-bens // Eur. J.Pharmacol. 1998. V.351. P. l63−171.
- Imazu Y., Moriuchi K., Nagao K., Murata S. et al. Comparative study of sulpiride and sultopride on dopamine turnover in the rat brain // Jap. J. Psychiat. Neurol. 1991. V.45. P.723−733.
- Imazu Y., Kobayashi K., Kawabata M., Shohmori I. Comparative study of sulpiride and haloperidol on cerebral dopamine turnover effects of acute and chronic administration / Jap.J.Psychiat.Neurol. 1988. V.42. P.378.
- Imperato A., Angelucci L. The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the prefrontal cortex of freely moving rats // Psychopharmacol .Bull. 1989. V.25. P.383−389.
- Iorio L.C., Barnett A., Leitz F.H., Houser V.P., Korduba C.A. SCH 23 390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems // J. Pharmacol.& Exp.Ther. 1983. V.226. P.462−468.
- Iversen S.D., Koob G.F. Behavioral implications of dopaminergic neurons in the mesolimbic systems // In: Costa E. Gessa G.L. (Eds). Nonstriatal dopaminergic neurons: Advances in biochemical psychopharmacology. Raven. N.Y. 1977. P.209−224.
- Jarvie K.R., Caron M.G. Heterogeneity of Dopamine receptors // Advances in Neurology (Eds.: Narabayashi H., Nagatsu Т., Yanagisawa Y.) Raven Press, N.Y. 1993. V.60. P.325−333.
- JennerP., Marsden C.D. Substituted benzamide drugs as selective neuroleptic agents//Neuropharmacol. 1981. V.20. P.1285−1293.
- Johansson A.M., Arvidsson L.E., Hacksell U., Nilsson J.L.G.et al. Novel dopamine receptor agonists and antagonists with preferential action on autoreceptors
- J. Med. Chem. 1985a. V.28. P.1049−1053.
- Johansson A.M., Arvidsson L.E., Nilsson J.L.G., Sanchez D. et al. Synthesis and pharmacology of the four stereoisomers of 5-hydroxy-l-methyl-2-(di-n-pro-pylamino)tetralin // Proc. VIII th Int. Symp. Med. Chem. Stockholm. 1985b. V.l. P.447−450.
- Johansson P., Casey D.E., Gunne L.M. Dose-dependent increases in spontaneous chewing rates during long-term administration of haloperidol but not clozapine // Psychopharmacol. Bull. 1986. V.22. P. 1017- 1019.
- Kaneno S., Komatsu H., Fukamauchi F., Ikawa K., Watanabe A. Biochemical basis of antidepressant effect of low dose sulpiride // Jap. J. Psychiat. Neurol. 1991. V.45.P.131−132.
- Kapur S., Zipurski R.B., Remihgton G., Jones C., DaSilva J., Wilson A.A., Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation//Am. J. Psychiatr. 1998. V.155. P.921−928.
- Karoum F., Egan M.F. Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens and striatum: a comparison of acute clozapine and haloperidol // Br. J. Pharmacol. 1992. V.105. P.703.
- Kebabian J.W. Pharmacological and biochemical chracterization of two categories of dopamine receptor // Dopamine Receptor Agonists. 1984. V.55. P.3−22.
- Kebabian J.W., CalneD.B. Multiple receptors for dopamine // Nature. 1979. V.277. P.93−96.
- Kebabian J.W., GreengardP. Dopamine-sensitive adenylate cyclase: Possible role in synaptic transmission // Sci. 1971. P.1346−1349.
- Kebabian J. W., Petzold G.L., GreengardP. Dopamine-sensitive adenylate cyclase in the caudate nucleus of rat brain and its similarity to the receptor // Proc. Natl. Acad. Sci. USA. 1972. V.69. P.2145−2149.
- Kehr W., Carlsson A., Lindquist M. Biochemical aspects of dopamine agonists // Adv. Neurol. 1975. V.9. P.185−195.
- Kelly A.E., Delfs J.M., Chu B. Neurotoxicity induced by the D-l agonist SKF 38 393 following microinjection into rat brain // Brain Res. 1990.V.532. P.342
- Kennedy J.S., Bymaster F.P., Schuh L., Caligaro D.O. et al. A current review of olanzapin’s safety in the geriatric patient: from pre-clinical pharmacology to clinical data // Int. J. Geriatr. Psychiatr. 2001. V. 16 (Suppl. 1) P. S33-S61.
- Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis // Psychopharmacol. 1996. V.124. P. l-34.
- KoeneP., PrinssenE., Cools A.R. Involvement of the nucleus accumbens in oro-facial behaviour in the rat // Psychopharmacol. 1990. V.101(Suppl.). P.30.
- KollerW., HerbsterG., Anderson D., WackR., Gordon J. Quinpirole hydrochloride, a potential anti-parkinsonism drug // Neuropharmacol. 1987. V.26. P.1031−1036.
- KoshikawaN., Koshikawa F., TomiyamaK., Kikuchi de B.K. et al. Effects of dopamine Di and D2 agonists and antagonists injected into the nucleus accumbens and globus pallidus on jaw movements of rats // Eur. J. Pharmacol. 1990a. V.182. P.375−380.
- KoshikawaN., MoriE., MaruyamaY., Yatsushige N., Kobayashi M. Role of dopamine D-1 and D-2 receptors in the ventral striatum in the turning behaviour of rats // Eur. J. Pharmacol. 1990b. V.178. P.233−237.
- KimuraK., Nomicos G.G., Svensson Т.Н. Effect of amperozide on psychosti-mulant-induced hyperlocovotion and dopamine release in the nuclens accumbens // PharmacoLBiochem. Behav. 1993.V.44. P.27−36.
- Kudrin V.S., Hetey L., Morgenstern R, Rayevsky K.S., Oelsner W. Effects of carbidine on dopamine biosynthesis in n. accumbens synaptosomes in the rat brain //Biogenic Amines. 1985. V.3. P.153−159.
- Kudrin V.S., Miroshnitchenko I.I., Gainnetdinov R.R., Bogdanov M.B. et al. Neurochemical profiles of carbidine stereoisomers: similarities and differences // Abst. 8 Soviet-Italian Meet, on Neuropsychopharmacol. Leningrad. 1990. P. 59.
- Kullingsjo H., Carlsson A., Svensson K. Effects of repeated administration of the preferential dopamine autoreceptor antagonist, (+)-AJ-76, on locomotor activity and brain DA metabolism in the rat // Eur. J. Pharmacol. 1991. V.205.1. Р.241−246.
- Kurata К., Shibata R. Effects of Di and D2 antogonists on the transient increase of dopamine release by dopamine agonists by means of brain dialysis // Neurosci. Lett. 1991. V.133.P.77−80.
- Kuroki Т., Meltzer H.Y., Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens // J. Pharmacol. Exp. Ther. 1999. V.288. P. 774−781.
- Lahoste G.J., Marshall J.F. Nigral Di and striatal D2 receptors mediate the behavioral effects of dopamine agonists // Behav. Brain Res. 1990. V.38. P.233−242.
- Lane R.F., Blaha C.D. Electrochemistry in vivo: application to CNS pharmacology // Ann.N.Y. Acad. Sci. 1986. V.473. P.50 -69.
- Levesque D., Diaz J., Pilon C., Martres M.P. et al. Identification, characterization of the dopamine D3 receptor in rat brain using 7- H. hydroxy-N, N-di-n-propyl-2-aminotetralin // Proc. Natl. Acad. Sci. USA. 1992. V.89. P.8155−8159.
- Li X.-M., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum // Psychopharmacol. 1998. V.136. P. 153−161.
- LiebmanJ., NealeR. Neuroleptic-induced acute dyskinesia in squirrel monkeys: correlation with propensity to cause extrapyramidal side effects // Psychopharmacol. 1980. V.68. P.25−29.
- LindeforsN., Sharp Т., UngerstedtU. Effects of subchronic haloperidol and sulpiride on regional brain dopamine metabolism in the rat // Eur. J. Pharmacol.1986. V. l29. P.401−404.
- Lindstrom L.H. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years // Acta Psychiatr. Scand. 1988. V.77. P.524−529.
- Lindvall O., BjorklundA. The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid fluorescence method // Acta Physiol. Scand. (Suppl.). 1974. V.412. P. 1−48.
- Lindvall O., Bjorklund A.K., Divac I. Organization of mesencephalic dopamine neurons projecting to neocortex and septum // Adv. Biochem. Psychophar-macol. 1977. V. l6. P.39−46.
- Lindvall O., BjorklundA., Moore R.Y., Stenevi U. Mesencephalic dopamine neurons projecting to neocortex // Brain Res. 1974. V.81. P.325−331.
- LjungbergT., UngerstedtU. Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action // Psychopharmacol.' 1978. V.56. P.239−247.
- MaldonadoR., Baamonde A., Dauge V., FegerJ. Effects induced by chronic treatment with selective Db or D2 antagonist on open-field behavior and colonic temperature // Fundam. Clin. Pharmacol. 1990. V.4. P.341−356.
- Markowitz J.S., Brown C.S., Moore T.R. Atypical antipsychotics. Part I: pharmacology, pharmacokinetics and efficacy // Ann. Pharmacother. 1999. V.33. P.73−85.
- Markstein R. Pharmacological characterisation of central dopamine receptors using functional criteria // In: The neurobiology of dopamine systems (Eds.: Winlow W., Marstein R.). Manchester, Manchester University Press, 1986. P.40−52.
- Martin G.E., Haubrich D.R., Williams M. Pharmacological profiles of the putative dopamine autoreceptor agonist 3-PPP and TL-99 // Eur. J. Pharmacol. 1981. V.76. P. 15−23.
- Matthysse S. Antipsychotic drug actions: A clue to the neuropharmacology ofschizophrenia?//Fed. Proc. 1973. V.32. P.200−205.
- McElroy S.L., Frye M.A., Denikoff K.D.S. et al. Olanzapine in treatment- resistant bipolar disorder // J. Affect. Disord. 1998. V.49. P. 119−122.
- Meltzer H.Y. Mechanism of action of novel antipsychotic drugs // Schizophr. Bull. 1991. V. 17. P.263−287.
- Meltzer H.Y., Stahl S.M. The dopamine hypothesis of schizophrenia // Schizophr. Bull. 1976. V.2. P. 19−76.
- Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia // Schizophren. Res. 1999. V.25. P.233−255.
- Memo M., Pizzi M., Missale C., Carruba M. et al. Pharmacological and functional basis of dopamine D2 diversity // Pharmacol. Res. 1990. V.22 (Suppl.). P.324.
- Miller R.J., McDermedJ.D. Dopamine-sensitive adenylate cyclase, In: The Neurobiology of Dopamine (Eds.: A.S.Horn, J. Korf, B.H.C.Westerink) // Academic Press, N.Y. 1979. P.159−177.
- MisuchiA., KitagawaN., Miyachi Y. Regional distribution of sultopride and sulpride in rat brain measured by radioimmunoassay // Psychopharmacol. 1983. V.81. P.195−198.
- Modenson G.J., Wu M. Effects of administration of dopamine D2 agonist quin-pirole on exploratory locomotion // Brain Res. 1991a. V.551. P.216−220.
- Modenson G.J., WuM. Quinpirole to the accumbens reduces exploratory and amphetamine-elicited locomotion // Brain Res. Bull. 1991b. V.27. P.743−746.
- Moghaddam В., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: an in vivo microdialysis study // J.Neurochem. 1990. V.54. P.1755−1760.
- Moore N.A., Axton M.S. The role of multiple dopamine receptors in apomor-phine and N-n-propylnorapomorphine-induced climbing and hypothermia // Eur. J. Pharmacol. 1990. V.178.P.195−201.
- Moore N.A., Calligaro D.O., Wong T.D., Bymaster F., Туе N.C. The pharmacology of olanzapine and other new antipsychotic agents // Curr. Opin. Invest. Drugs. 1993. V.2 P.281−293.
- Moore N. A., Rees G., Sanger G. Differential effects of olanzapine and other new antipsychotic agents on stimulant-induced hyperactivity // Psychopharmacol.1994. V.8 (Suppl.). P. S29.
- Moratalla R., Xu M., Tonegawa S., Graybiel A.M. // Soc. Neurosci. Abstr.1995. V.21. P.1905.
- Morelli M., Carboni E., Devete S., Di Chiara C. 6-Hydroxydopamine lesions reduce specific 3H-sulpiride binding in the rat substantis nigra: direct evidence for the existence of nigral D-2 autoreceptors // Eur. J. Pharmacol. 1987. V. l40. P.99−104.
- Motohashi N., Takashima M., Mataga N., Nishikawa T. et al. Effects of sulpiride and oxypertine on the dopaminergic system in the rat striatum // Neuropsycho-biol. 1992. V.25. P.29−33.
- Murray A.M., Waddington J.L. New putative selective agonists at the D-l dopamine receptor: behavioral and neurochemical comparison of CY 208 with SKF 101 384 and SKF 103 243 //Pharmacol. Biochem. Behav. 1990. V.35. P.105−110.
- Nagai Y., Irie A., Masuda Y., Oka M., Uno H. Synthesis of 2,3,4,4a, 5,9b-hexa-hydro-lH-pyrido 4,3b. indole derivatives and their central nervous system activities // J. Med. Chem. 1979. V.22. P.677−683.
- Needham P.L., Skill M.J., Cowan A., Redfern R.J., Heal D.J. Reserpinization severes the oppositional interaction between Di and D2 receptors // Neurophar-macol. 1993. V.32. P.515−517.
- Ninan I., Kulkarni S.K. Preferential inhibition of dizocilpine-induced hyper-locomotion by olanzapine // 1999. V.368. P. 1−7
- Nomoto M., Jenner P., Marsden D. Alterations in motor behaviour produced by the isomers of 3-PPP in the MPTP-treated marmoset // Eur. J. Pharmacol. 1986. V.121. P.123−128.
- Nordstrom A.L., Farde L., Nyberg S., Karlsson P., Halldin C., Sedvall C. Dl, D2 and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenia patients // Am. J. Pharmacol. 1995. V.152. P.1444−1449.
- Noordsy D.L., O’Keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental center setting // J. Clin. Psychiatr. 1999. V.60 (Suppl.). P.47−53.
- NunesJ.L., Sharif N. A., Michel A.D., Whiting R.L. Dopamine D2-receptors mediate hypothermia in mice: ICV and IP effects of agonists and antagonists // Neurochem. Res. 1991. V.16. P. l 167−1174.
- Ogren S.O., Hall H., Kohler C., Magnusson O. et al. Die selektiven antidopa-minergen Eigenschaften von Remoxiprid, einem neuen moglichen antipsycho-tischen Wirkstoff//Arzneimitt. Forsch. 1985. V.35. P.1227−1231.
- Ogren S.O., Hall H., Kohler C. et. al. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain // Eur. J. Pharmacol. 1984. V.102. P.459−474.
- Panteleeva G.P., Tsutsulkovskaya M.Y., Belyaev B.S., Minsker E.I. Clozapine in the treatment of schizophrenic patients: an international multicenter trial // Clin. Ther. 1987. V.10. P.57−68.
- Petrovic J., TomicM., Soskic V. Dopamine receptors // Acta biol. yugoslav. 1990. V.26. P.387−410.
- PierceyM.F., Lum J.T. Electrophysiological effects of dopamine autoreceptor antagonists, (+) AJ-76 and (+) UH-232 // Eur. J. Pharmacol., 1990a. V.182. P.219−226.
- Pierce R., Rebec G.V. Stimulation of both Dj and D2 dopamine receptors increases behavioral activation and ascorbate release in the neostriatum of freely moving rat // Eur. J. Pharmacol. 1990b. V.191. P.295- 302.
- Pletnikov М., Storozheva Z., Gainetdinov R., Sotnikova Т., Rayevsky K. // Behav. Pharmacol. 1995. V.6. Suppl.l. P.37−38.
- RedolatR., Brain P.F., Simon V.M. Sulpiride has an antiaggressive effect in mice without markedly depressing motor activity // Neuropharmacol. 1991. V.30. P.41−46.
- Reynolds G.P., Czudek C. New approaches to the drug treatment of schizophrenia//Adv. Pharmacol. 1995. V.13. P.461−503.
- Reynolds G.P., Garrett N.J., Rupniak N., Jenner P., Marsden C.D. Chronic clozapine treatment of rats down-regulates cortical 5 HT2 receptors // Eur. J. Pharmacol. 1983. V.89. P.325.
- Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects // J. Clin. Psychiat. 1999. V.60 (Suppl.10). P.5−14.
- Robertson G.S., Fibiger H.C. Effects of olanzapine on regional C-Fos expression in rat forebrain // Neuropsychopharmacol. 1996. V.14. P. 105−110.
- Robertson G.S., Fibiger H.C. Neuroleptic increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine // Neurosci. 1992. V.46. P.315−328.
- Roth R.H. Neuroleptics: Functional Neurochemistry // In.: Neuroleptics, Behavioral and Clinical Perspectives. (Eds.: J.T.Coyle, S.J.Enna). Raven Press, N.Y. 1983. P.119−156.
- Rolls E.T., Cooper S.J. Activation of neurons in the prefrontal cortex by brain stimulation reward in the rat // Brain Res. 1973. V.60. P.351−368.
- Ross J., Baldessarini M.D., Frances R., Frankenburg M.D. Clozapine: a novel antipsychotic agent//N.Engl .J. Med. 1991. V.324. P.746.
- Sailer C.F., Salama A.l. Dopamine receptor subtypes: in vivo biochemical evidence for functional interaction // Eur. J. Pharmacol. 1985. V.109. P.297−300.
- Sanger D.J. The effects of clozapine on shuttle-box avoidance responding in rats: comparisons with haloperidol and chlordiazepoxide // Pharmacol, Biochem. Behav. 1985. V.23. P.231−236.
- SasaM., HaraM., Takaori S. Dopamine D-1 receptor-mediated inhibition of nucleus accumbens neurons from the ventral tegmental area // Progr. Neuropsy-chopharmacol. Biol. Psychiat. 1991. V.15. P. l 19−128.
- Sautel F., Griffon N., Levesque D., Pilin C. et al. A functional test identifies dopamine agonists selective for D3 versus D2 receptors // Neuroreport. 1995. V.6. P.329−332.
- Schrenimer C., Morgenstern R., Fink H., Off T. Atypical neuroleptics suppress dopaminergic behavioral supersensitivity // Psychopharmacol. 1990. V.100. P. 399−403.
- See R.E., Ellison G. Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride in an animal model of tardive dyskinesia // Eur. J. Pharmacol 1990. V.181. P. l75−186.
- SeemanP. Brain dopamine receptors // Pharmacol. Rev. 1980. V.32. P.229−313.
- Seeman P., List S., Multiple receptor for dopamine (D2, D3, D4) In: Advancesin Dopamine Research (Kohsaka M., Tsukada Y. and Woodruff G.N., Eds), Per-gamon Press, Oxford. 1982. P.61−70.
- Seeman P., Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to D2 receptors, yet occupy high levels of these receptors // Mol.Psychiat. 1998. V.3. P. 123−124.
- Seeman P., Tallerico T. Rapid release of antipsychotic drugs from D2 receptors, an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine and quetiapine // Am. J. Psychiatry. 1999. V. l 56. P.876−884.
- Shippenberg T.S., Bals-Kubik R., Huber A., Herz A. Neuroanatomical substrates mediating the aversive effects of D-l dopamine receptor antagonists // Psy-chopharmacol. 1991. V.103. P.209−214.
- Sibley D.R. La clonazione di un sottotipo di recettore D3 amplia la famiglia dei recettori della dopamina // G. Neuropsicofarmacol. 1992. V. 14. P. 11−14.
- Simon H., Stinus L., Tassin J.P., Blanc G. et al. Are the mesocorticolimbic dopaminergic neurons necessary for brain stimulation reward? Abstr. Of XXVII Int. Congr. of Physiol. Sci. Paris. 1977.
- Skirboll L.R., Grace A.A., Bunney B.S. Dopamine auto- and postsynaptic receptors: Electrophysiological evidence for differential sensitivity to dopamine agonists // Sci. 1979. V.206. P.80- 82.
- Skura G., Rogoz Z., Zak J. Effect of antidepressant drugs and different receptor antagonists on the grooming induced by the dopamine D-l agonist SKF 38 393 // Pol. J. Pharmacol. Pharm. 1989. V.41. P.421−429.
- Snyder S.H. Amphetamine psychosis: schizophrenia mediated by catecholamines // Am. J. Psychiat. 1973. V.130. P.61−67.
- Sokoloff Т., Giros В., Martres M.P., Schwart J.Ch., Bouthenet M.L. Le troisie-me recepteur de la dopamine Une nonvelle cible d’action des neuroleptiques // Med. Sci (Fr.). 1990. V.6. P.800−802.
- Sokoloff P., Martres M.P., Giros В., Bouthenet M.L., Schwartz J.C. The third dopamine receptor (D3) as a novel target for antipsychotics // Biochem. Pharmacol. 1992. V.43. P.659−666.
- Sotnikova Т., Gainetdinov R., Grekhova Т., Rayevsky K. Effects of intrastria-tal infusion of D2 and D3 dopamine receptors preferring antagonists on dopamine release in rat dorsal striatum // Pharmacol. Res. 2001. V. P.283−290.
- Souto M., Montim J.M., Altier H. Effects of clozapine on the activity of central dopaminergic and noradrenergic neurons // Pharmacol. Biochem. Behav. 1979. V.10. P.5−9.
- Spooren W.P.J.M., Piosik P.A., Cools A.R. Dopamine Dj receptors in the subcommissural part of the globus pallidus and their role in oro-facial dyskinesia in cat//Eur. J. Pharmacol. 1991. V.204. P.217−222.
- Srivastava A.K., Srivastava Y.P., CuptaP.P., VermaR.B. Characterization of dopamine receptors involved in central thermoregulation in rabbits // Indian J. Exp. Biol. 1991. V.29. P.1087- 1088.
- Stahle L., Ungerstedt U. Effects of neuroleptic drugs on the inhibition of exploratory behaviour induced by low dose of apomorphine: implications for the identity of dopamine receptors // Pharmacol. Biochem. Behav. 1986. V.25. P.473−480.
- Stange P.G. Interesting times for dopamine receptors // Trends Neurosci. 1991. V.14. P.43−45.
- Steke K., Reimann W., Zumstein A., Hertting G. Effect of dopamine receptor agonists and antagonists on release of dopamine in the rabbit caudate nucleus in vivo //Naunyn-Schmiedeberg's Arch.Pharmacol. 1978. V.305. P.27−36.
- Stockton M.E., Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons // Neuropsycho-pharmacol. 1996. V.14. P.97−104.
- Stoff J.C., Kebabian J.W. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum // Nature. 1981. V.294. P.366−368.
- Suarez-Roca H., Lovenberg Т., Cubeddu L.X. Comparative dopamine-cholinergic mechanisms in the olfactory tubercle and the striatum: effects of metaclo-pramide //J. Pharmacol. Exp. Ther. 1987. V.243. P.840−851.
- Sunahara R.K., Guan H.C., O’Dowd B.F. et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 // Nature (London). 1991. V.350. P.614−619.
- Svensson K., Hjorth S., Clark D., Carlsson A., Wikstrom H. et al. (+) -UH 232 and (+) UH242: Novel stereoselective dopamine receptor antagonists with preferential action on autoreceptors // J. Neural. Transm. 1986b. V.65. P. 1−27.
- Svensson K., Johansson A.M., MagnussonT., Carlsson A. (+)-AJ76 and (+) -UH232: Central stimulants actions as preferential dopamine autoreceptor antagonists // Naunyn-Schmiedeberg's Arch. Pharmacol. 1986c. V.334. P.234−245.
- Tamminga C.A. Atypical neuroleptics and novel antipsychotic drugs // Neuroleptics: neurochemical, behavioural and clinical perspectives. (Eds.: J.T.Coyle and S.J.Enna) Raven Press, N.Y. 1983. P.281.
- Tamminga C.A., Gerlach J., New neuroleptics and experimental antipsychotics in schizophrenia // Psychopharmacology: the third generation of progress. (Ed. H.Y.Meltzer). Raven Press, N.Y. 1987. P. l 129−1138.
- Tanaca Т., Vincent S.R., Nomicos G.G., Fibiger H.C. Effect of quinine on au-toreceptor-regulated dopamine release in the rat striatum // J.Neurochem. 1992. V.59. P. l640- 1645.
- Tandon R., Harrigan E., Zorn S. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutical potential // J. Serotonin Res. 1997. V.4. P.159−177.
- Tauscher J., Kufferle В., asenbaum S. In vitro 1231IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated witholanzapine in comparison to clozapine and haloperidol I I Psychopharmacol. 1999. V.141. P.175−181.
- Thierry A., M., Blanc G., Sobel A., Stinus L., Glowinski J. Dopaminergic ter-minalis in the rat cortex // Sci. 1973a. V. l82. P.499- 501.
- Thierry A.M., Stinus L., Blanc G., Glowinski J. Some evidence for the existence of dopaminergic neurons in the rat cortex // Brain Res. 1973b. V.50. P.230−234.
- Thierry A.M., Tassin J.P., Blanc G., Glowinski J. Studies on mesocortical dopamine systems // In.: Adv. in Biochem. Psychopharmacol. (Eds. Roberts P.J., Woodruff G.N., Iversen L.L.). Raven Press, N.Y. 1978. V. l9. P.205−216.
- Todd D.R., O’Malley K.L. Family Ties: The dopamine D2-like receptor genes //Neurotransmiss. 1993. V.9. P. 1−4.
- Tollefson G., Taylor C. Olanzapine: preclinical and clinical profiles of a novel antipsychotic agent // CNS Drug Rev. 2000. V.6. P.303−364.
- Tollefson G., Beasley C.M., Tran P. et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial // Am. J. Psychiatr. 1997. V. l54. P.457−465.
- Tollefson G., Deliva M.A., Mattler C.A. et al. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo // J. Clin. Pharmacol. 1999. V.19. P.435−443.
- TsurutaK., FreyE.A., Grewe C.W., Cote Т.Е. et al. Evidence that Ly 141 865 specifically stimulates the D2 dopamine receptor // Nature. 1981. V. 292.1. Р.463.
- UngerstedtU. Central dopamine mechanisms and unconditioned behaviour I I In: Horn A.S., Korf J., Westerink B.H.C. (Eds.) The neurobiology of dopamine. Academ. Press, London. 1979. P.577−596.
- Vaccheri A., Dall’Olio R., Gandolfi O., Montanaro N. Involvement of different dopamine receptors in rat diphasic motility response to apomorphine // Psychopharmacol. 1986. V.89. P.265−268.
- Van TolH.H.M., Wu C.M., GuanH.Ch., OharaK. et al. Multiple dopamine D4 receptor variants in the human population // Nature. 1992. V.358. P.149−152.
- Vasse M., Chagraoui A., Protais Ph. Climbing and stereotyped behaviours in mice require the stimulation of Dj dopamine receptors // Eur. J. Pharmacol. 1988. V.142. P. 221−229.
- Vasse M., Protais Ph., Costentin J. and Schwartz J.C. Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice // Naunyn-Schmiedeberg's.Arch. Pharmacol. 1985. V.329. P.108.
- Verma A., Kulkarni S.K. Dopamine receptor mediated hypothermic action of B-HT 920 in rat // J. Pharm. Pharmacol. 1991. V.43. P.421−424.
- Wachtel H. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans // J. Neural. Transm. 1991. V.3. P. I51−201.
- Waddington J.L. Behavioral correlates of the action of selective Dj dopamine receptor antagonists // Biochem. Pharmacol. 1986.V.35. P.3661−3667.
- Wadenberg M. Effects of raclopride and haloperidol on spontaneous motor activity and conditioned avoidance behavior in rat // Arzneimitt. Forsch. 1991. V.41. P.692−695.
- Walters J.R., Roth R.H. Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors // Naunyn-Schmiedeberg's Arch. Pharmacol. 1976. V.296. P.5−14.
- Waltling K.J., Beer M.S., Stanton J.A., Newberry N.R. Interaction of the atypical neuroleptic clozapine with 5-НТз receptors in the cerebral cortex and superior cervical ganglion of the rat // Eur. J. Pharmacol. 1990. V. l 82. P.465−472.
- WanibuchiF., Usuda Sh. Synergistic effects between D-1 and D-2 dopamine antagonists on catalepsy in rats // Psychopharmacol. 1990. V. l02. P.339−342.
- WatanabeH., SudaH., SekiharaS., Nomura Y. Dj type of dopamine autore-ceptors are not involved in the regulation of dopamine synthesis in the striatum // J. Pharmacol. 1987. V.43. P.327−330.
- Waters N., LoffergL., SvenssonK., CarlssonA. Increased dopamine release by the autoreceptor antagonist (+) AJ-76 is Ca -dependent // Eur. J. Pharmacol.1990. V. l87. P.425−434.
- Welch W.M., Harbert C.A., Weissman А., Кое B.K. Neuroleptics from the 4a, 9b-cis- and 4a, 9b-trans- 2, 3, 4, 4a, 5, 9b -hexahydro -lHpyrido 4,3-b. indole series // J. Med. Chem. 1986. V.29. P.2093- 2099.
- White F.J., Ни X.T., Brooderson R.J. Repeated stimulation of dopamine Di receptors enhances the effects of dopamine receptor agonists // Eur. J. Pharmacol.1991. V. 191. P.497−499.
- White F.J., Wang R.Y. Differential effects of classical and atypical drugs on A9 and A10 dopamine neurons. 1983. V.221. P.1054−1057.
- Wilk S., Watson E., Stanley M.E. Differential sensitivity of two dopaminergic structures in rat brain to haloperidol and to clozapine II J. Pharmacol. & Exp. Ther. 1975. V.195. P.265−270.
- WillemsJ.L., Buylaert W.A., Lefebvre R.A., BogaertM.G. Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system // Pharmacol.Rev. 1985. V.37. P.165−216.
- WilmotC.A., Szczepanik A.M. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in ratbrain // Brain Res. 1989. V.487. P.288−298.
- Winn P. Schizophrenia research moves to the prefrontal cortex // Trends Neural Sci. 1994. V. l7. P.265−268.
- Woodruff G.H., Andrews C.D. Some effects of sulpiride on dopaminergic systems: Comparison with other neuroleptics // Sulpiride and other benzamides. (Eds. P.F.Spano, M. Trabucchi, G.U.Corsini and G.L.Gessa). Raven Press, N.Y. 1979. P.33−46.
- Zarrindast M.R., Habibi-Moini S. Blockade of both D-l and D-2 dopamine receptors may induce catalepsy in mice // Gen. Pharmacol. 1991a. V.22. P. 10 231 026.
- Zarrindast M.R., Minaian A. Different effects of direct and indirect dopamine receptor agonists on immobility time in reserpine treated mice // Gen. Pharmacol. 1991b. V.22. P.1017−1021.